MediWound

Company Overview

Snapshot

Founded in January 2000, MediWound operates with 51–200 employees and has raised a total of $198.72 million across 8 funding rounds. The company went public on NASDAQ in March 2014, marking a significant milestone in its journey to commercialize enzymatic therapies.

Business overview

MediWound is a global biotechnology company focused on pioneering enzymatic, non-surgical therapies for tissue repair. Its core product, NexoBrid, is an FDA-approved biologic for the enzymatic removal of eschar in thermal burns, marketed across the United States, European Union, Japan, and other international markets. The company is also developing EscharEx, an investigational therapy for chronic wound debridement, aiming to establish a new standard of care in wound management. MediWound operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and biomaterials for patients.

Strategic signal

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid. This expansion signals a significant increase in production capacity, indicating strong market demand and the company's commitment to scaling its flagship product. For investors, this suggests a positive outlook for future revenue growth and operational efficiency.

Company Intelligence Q&A

What was a significant recent financial event for MediWound?

In September 2025, MediWound announced a $30 million registered direct offering of ordinary shares.

What is the status of MediWound's NexoBrid product in Australia?

In September 2025, MediWound expanded its global reach with marketing approval of NexoBrid in Australia.

What is the latest update on MediWound's manufacturing capabilities?

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid.

What collaboration did MediWound announce regarding its EscharEx product?

In October 2023, MediWound announced a collaboration with 3M on the EscharEx Phase III Study.

What was a key strategic partnership for NexoBrid distribution in Europe?

In November 2023, MediWound announced a collaboration with PolyMedics Innovations (PMI) for NexoBrid distribution in Europe.